UNSPSC 51432602: Terciprazine

This classification denotes an antihypertensive agent with the molecular formula C22H29F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TCE6830H8P, chemically known as (+-)-alpha-(((1-ethynylcyclohexyl)oxy)methyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazineethanol but generally known as terciprazine, which bears US NIH Compound Identifier 68763. European Medicines Agency schedules Terciprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10916MIG.

UNSPSC 51432602 Terciprazine, a Commodity code, covers prescription and over-the-counter medications that state and local governments procure for emergency medical services, health and human services programs, and institutional care. State and local purchasing activity under this code centers on direct procurement of branded and generic pharmaceuticals in bulk quantities to support fire rescue operations, state health programs, and cooperative purchasing alliances serving multiple jurisdictions. Issuing bodies include municipal fire departments, state health agencies, and multistate cooperative purchasing entities. The work involves competitive solicitation of specific medications by National Drug Code, management of expiration dates and shelf-life requirements, compliance with FDA and manufacturing standards, and establishment of supply and delivery terms.

State and local procurement under the code spans multiple regions. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 seeking Advanced Life Support Medications for Tampa Fire Rescue in Hillsborough County, Florida—including epinephrine, labetalol, adenosine, and diltiazem injections and vials with nine-month minimum expiration dates and ten-calendar-day delivery, closing April 8, 2026, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs for state pharmacy benefit operations, signaling exploratory procurement activity ahead of formal competitive solicitation.